Cyclo Therapeutics: Rises on launching late-stage study of genetic disorder treatment

Cyclo Therapeutics

17/06/2021 13:52

** Shares of drug developer  CYTH.O  jump 3.7% to $10.58
premarket
    ** Co begins patient enrollment in late-stage study testing
its lead candidate, Trappsol Cyclo, to treat Niemann-Pick
Disease Type C1  urn:newsml:reuters.com:*:nBw92q5R7a
    ** Niemann-Pick disease type C is a progressive genetic
disorder characterized by inability of body to transport
cholesterol and other fatty substances inside cells
    ** Approx 95% of cases are caused by mutations in the NPC1
gene, referred to as type C1
    ** Co intends to enroll at least 93 pediatric and adult
patients in study and report results from interim analysis in
the H1 of 2023
    ** CYTH had more than doubled this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))